Healthcare >> Analyst Interviews >> April 11, 2019
Data Readouts from CRISPR Trials Will Be Critical in 2019
Manisha Samy is an Analyst at ARK Investment Management LLC. Ms. Samy joined ARK as a thematic analyst on the Genomic Revolution team in February 2016. Her focus is on gene editing, gene therapy, instrumentation, targeted therapeutics, agricultural biology, diagnostics and stem cells. Prior to ARK, Ms. Samy worked as a management consultant for Kepler Cannon. Before that, she gained experience as a business solution analyst at Attensity America. Ms. Samy graduated from Stanford with a Bachelor of Science in science, technology and society: life sciences and biotechnology. She has spent eight years in Stanford’s research lab studying stem cells in acute myeloid leukemia. Profile
Word count: 3,640
TWST: What is your coverage universe?
Ms. Samy: Our entire strategy is focused on the genomic revolution and its key technology enablers, but